Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859239 | 0.96 | FFAR4 (0.46) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL7711638 | 0.90 | HDAC6 (0.46) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL6860110 | 0.83 | HDAC1 (0.44) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL22660216 | 0.81 | HDAC1 (0.43) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL7899314 | 0.81 | HDAC1 (0.72) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| Hydroxyamine SCHEMBL2880441 | 0.78 | HDAC1 (0.68) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| Hydroxyamine SCHEMBL15764650 | 0.78 | HDAC1 (0.68) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL28337704 | 0.77 | CYP2D6 (0.47) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL7708661 | 0.75 | LMNA (0.47) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL28590360 | 0.73 | HDAC2 (0.44) | HDAC1HDAC6HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | ITGB1, ITGA1, ITGB3 | HDAC1 98/4885HDAC6 306/4885HDAC2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.